ArticleOncology letters2018
Potential tumor suppressing role of microRNA-545 in epithelial ovarian cancer.
Article in Oncology letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- RP5-1148A21.3 (lncRP5) exerts oncogenic function in human ovarian carcinoma.Acta biochimica et biophysica Sinica · 2022Article
- Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2.Journal of immunology research · 2022Article
- Blocking circ_0014130 suppressed drug resistance and malignant behaviors of docetaxel resistance-acquired NSCLC cells via regulating miR-545-3p-YAP1 axis.Cytotechnology · 2021Article
- Review
- Prognostic and Functional Significant of Heat Shock Proteins (HSPs) in Breast Cancer Unveiled by Multi-Omics Approaches.Biology · 2021Article
- Article
- LncRNA NR2F2-AS1 induces epithelial-mesenchymal transition of non-small cell lung cancer by modulating BVR/ATF-2 pathway via regulating miR-545-5p/c-Met axis.American journal of cancer research · 2021Article
- Long non-coding RNA PTPRG-AS1 promotes cell tumorigenicity in epithelial ovarian cancer by decoying microRNA-545-3p and consequently enhancing HDAC4 expression.Journal of ovarian research · 2020Article
- Hsa_circ_0003732 promotes osteosarcoma cells proliferation via miR-545/CCNA2 axis.Bioscience reports · 2020Article
- Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line.Scientific reports · 2019Article
- miR-205-3p promotes proliferation and reduces apoptosis of breast cancer MCF-7 cells and is associated with poor prognosis of breast cancer patients.Journal of clinical laboratory analysis · 2019Article
- MicroRNA-545 targets ZEB2 to inhibit the development of non-small cell lung cancer by inactivating Wnt/β-catenin pathway.Oncology letters · 2019Article
- Tumor suppressor role of microRNA-545 in oral squamous cell carcinoma.Oncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer, which exhibits invasive traits. MicroRNAs (miRNAs/miRs) have been demonstrated to serve important functions in the pathogenesis of EOC. However, the function of miR-545 in EOC remains unknown. In the present study, the function of miR-545 in EOC was analyzed and it was identified that miR-545 is downregulated in EOC tissues and cell lines. Additionally, a low level of miR-545 expression was associated with a low survival rate of patients with EOC. Furthermore, overexpression of miR-545 inhibited cell growth and promoted apoptosis. Suppression of miR-545 promoted cell growth and inhibited apoptosis. Additionally, the RAC-γ serine/threonine-protein kinase gene was targeted by miR-545. Thus, it may be concluded that miR-545 exhibited antitumor traits in EOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.